Sanford first in the nation to dose patient with SAB’s COVID treatment
A first-of-its-kind approach to targeting COVID-19 has happened between two Sioux Falls-based organizations.
A first-of-its-kind approach to targeting COVID-19 has happened between two Sioux Falls-based organizations.
Sioux Falls-based POET and Farmers Business Network, which has a large office in the city, are working together on a new network.
Avera Health will be part of three phase two and three clinical trials evaluating whether a combination of two lab-made antibodies can not only treat, but also prevent SARS-CoV-2, the virus that causes COVID-19.
He watched his dad work long hours on the farm and thought there had to be a better way. Now, at 26, he’s a record-setting entrepreneur in South Dakota.
Avera’s cancer research has a new leader with a big vision to bring new trials and treatments to the region.
Sioux Falls-based SAB Biotherapeutics has started testing in a human patient for its therapeutic specifically developed for the virus that causes COVID-19.
Sioux Falls-based SAB Biotherapeutics has received an additional $35.6 million in government funding, plus $14 million in series B funding that includes a new investor – global health care leader Merck.
This team takes on the tough but valuable work of helping organizations fundraise – with impressive results.
A new study from Sanford Research will try to determine the prevalence of COVID-19 and learn more about its antibodies.